| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Experimental Pathology and 2 Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden
Requests for reprints: Janna Dejmek, Experimental Pathology, Department of Laboratory Medicine, Lund University, U-MAS, Entrance 78, SE-205 02 Malmö, Sweden. Phone: 46-40-337-651; Fax: 46-40-337-353; E-mail: Janna.Dejmek{at}med.lu.se.
Oncogenic Wnt/ß-catenin signaling occurs in a majority of colorectal cancers. In contrast, very little is known about the role of the nontransforming Wnt protein family member Wnt-5a in those tumors. In the most common of the three colon cancer stages, Dukes B or lymph nodenegative, the outcome is the hardest to predict. We searched for a predictive marker in this group and observed loss of or reduced Wnt-5a expression in 50% of Dukes B tumors. Such Wnt-5a negativity was a strong predictor of adverse outcome, with a relative risk of death of 3.007 (95% confidence interval, 1.336-6.769; P = 0.008) after 5 years in Wnt-5a-negative patients. Furthermore, the median survival time after diagnosis was 109.1 months for patients with Wnt-5a-positive primary tumors but only 58 months for those with Wnt-5a-negative primary tumors. To find a possible biological explanation for these results, we studied the invasive and poorly differentiated human colon cancer cell line, SW480, which does not express Wnt-5a protein and the Wnt-5a-expressing and moderately differentiated Caco2 colon cancer cell line. We found that the addition of recombinant/purified Wnt-5a significantly reduced the migratory capacity of SW480 cells. By comparison, equivalent treatment did not significantly alter migration in the Wnt-5a-expressing Caco2 colon cancer cell line. These findings indicate that the expression of Wnt-5a in primary Dukes B colon cancer tissue constitutes a good prognostic marker for longer survival, which can be explained by the ability of Wnt-5a to impair tumor cell migration and thus reduce invasiveness and metastasis.
This article has been cited by other articles:
![]() |
V. Jenei, V. Sherwood, J. Howlin, R. Linnskog, A. Safholm, L. Axelsson, and T. Andersson A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion PNAS, November 17, 2009; 106(46): 19473 - 19478. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Medrek, G. Landberg, T. Andersson, and K. Leandersson Wnt-5a-CKI{alpha} Signaling Promotes {beta}-Catenin/E-Cadherin Complex Formation and Intercellular Adhesion in Human Breast Epithelial Cells J. Biol. Chem., April 17, 2009; 284(16): 10968 - 10979. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Ford, E. J. Ekstrom, and T. Andersson From the Cover: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells PNAS, March 10, 2009; 106(10): 3919 - 3924. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Safholm, J. Tuomela, J. Rosenkvist, J. Dejmek, P. Harkonen, and T. Andersson The Wnt-5a-Derived Hexapeptide Foxy-5 Inhibits Breast Cancer Metastasis In vivo by Targeting Cell Motility Clin. Cancer Res., October 15, 2008; 14(20): 6556 - 6563. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. I. Pacheco and R. J. MacLeod CaSR stimulates secretion of Wnt5a from colonic myofibroblasts to stimulate CDX2 and sucrase-isomaltase using Ror2 on intestinal epithelia Am J Physiol Gastrointest Liver Physiol, October 1, 2008; 295(4): G748 - G759. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, L. Wang, S. Zhang, J. Lin, S. Zhang, M. A. Feitelson, H. Gao, and M. Zhu Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses Carcinogenesis, June 1, 2008; 29(6): 1207 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ying, H. Li, J. Yu, K. M. Ng, F. F. Poon, S. C. C. Wong, A. T.C. Chan, J. J.Y. Sung, and Q. Tao WNT5A Exhibits Tumor-Suppressive Activity through Antagonizing the Wnt/ -Catenin Signaling, and Is Frequently Methylated in Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 55 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. MacLeod, M. Hayes, and I. Pacheco Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G403 - G411. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Stoick-Cooper, G. Weidinger, K. J. Riehle, C. Hubbert, M. B. Major, N. Fausto, and R. T. Moon Distinct Wnt signaling pathways have opposing roles in appendage regeneration Development, February 1, 2007; 134(3): 479 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kurayoshi, N. Oue, H. Yamamoto, M. Kishida, A. Inoue, T. Asahara, W. Yasui, and A. Kikuchi Expression of Wnt-5a Is Correlated with Aggressiveness of Gastric Cancer by Stimulating Cell Migration and Invasion Cancer Res., November 1, 2006; 66(21): 10439 - 10448. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dejmek, A. Safholm, C. Kamp Nielsen, T. Andersson, and K. Leandersson Wnt-5a/Ca2+-Induced NFAT Activity Is Counteracted by Wnt-5a/Yes-Cdc42-Casein Kinase 1{alpha} Signaling in Human Mammary Epithelial Cells. Mol. Cell. Biol., August 1, 2006; 26(16): 6024 - 6036. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Safholm, K. Leandersson, J. Dejmek, C. K. Nielsen, B. O. Villoutreix, and T. Andersson A Formylated Hexapeptide Ligand Mimics the Ability of Wnt-5a to Impair Migration of Human Breast Epithelial Cells J. Biol. Chem., February 3, 2006; 281(5): 2740 - 2749. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |